06.26.26 -- Can Molecular Glue Degraders Make The Undruggable Druggable?

Standardized analytical data is key to improving data quality, reuse, and AI readiness. Explore the challenges of fragmented formats and gain practical guidance on building future-proof foundations.

An experienced industry leader shares insights on how biosimilars are reshaping healthcare through scale, manufacturing discipline, supply reliability, and long‑term commercial strategy.

Medtech OEMs, contract manufacturers, and other partners involved in the device life cycle are increasingly realizing additional benefits by making sustainability a group exercise.

Ensure product quality and patient safety by examining the FDA's draft guideline on Computer Software Assurance that emphasizes a risk-based approach to streamline software validation.

What are the benefits of using automated product data management and quality management system software solutions in manufacturing?

Improve purification workflows for complex GLP‑1 peptides with practical guidance. Learn how to boost resolution, uncover hidden impurities, and increase yield across analytical and preparative workflows.

A preview of AAPS PharmSci 360 2026 highlighting formulation science, patient‑centric oral dosage forms, and strategies for translating early research into scalable, manufacturable drug products.

Nitrosamines are a serious risk in drug products, driven by the presence of secondary amines, conducive conditions, and nitrosating agents. Understanding these factors is key to risk mitigation.

Risk in outsourced drug development is often created, not inherent. Delve into how CDMO structure, continuity, and communication directly affect programme risk, timelines, and outcomes.

Discover how integrated containment, expertise, advanced chromatography, and proven linker–payload process optimization can accelerate your program from development to commercial supply.

A practical USP <1665> and <665> framework helps manufacturers evaluate and manage extractables and leachables risk, supporting quality, safety, and regulatory compliance.

In GMP operations, poor asset control quickly becomes a compliance risk. Learn how maintenance and calibration gaps lead to deviations and why demonstrable asset performance is essential.

Life sciences compliance is complex and ever-changing. Read about how modern solutions can streamline processes, reduce friction, and keep your organization ahead of regulatory demands.

Uncover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

A standardized, multi-plant biomanufacturing model enables faster timelines, greater flexibility, and consistent global quality, turning CDMO partnerships into a sustained competitive advantage.